AA
HALO icon

AlphaCentric Advisors’s Halozyme HALO Stock Holding History

AlphaCentric Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$738K Buy
9,426
+4,632
+97% +$316K 0.63% 45
2026
Q1 		$310K Buy
4,794
+261
+6% +$18.4K 0.31% 107
2025
Q4 		$305K Buy
+4,533
New +$305K 0.3% 104

Other funds holding HALO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

AlphaCentric Advisors's HALO Position: Q2 2026 in Review

AlphaCentric Advisors increased its Halozyme (HALO) stake by 97% in Q2 2026, buying an estimated $316K and bringing the position to 9,426 shares worth $738K. The position accounts for 0.63% of the portfolio, ranked #45.

AlphaCentric Advisors first reported a position in HALO in Q4 2025 and has held it in 3 quarters since. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • AlphaCentric Advisors held 9,426 shares of Halozyme worth $738K as of Q2 2026.
  • AlphaCentric Advisors bought 4,632 Halozyme shares in Q2 2026, an estimated $316K.
  • Halozyme made up 0.63% of AlphaCentric Advisors's portfolio in Q2 2026, its #45 holding.
  • AlphaCentric Advisors first reported a position in Halozyme in Q4 2025 and has held it in 3 quarters since.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.